VJVirtual | GISTs offer a promising evidence base for biomarkers of response to therapy in sarcomas

Robin Jones • 1 May 2025

Robin Jones, MD, The Royal Marsden Hospital, London, UK, comments on the biomarkers of response to therapy in sarcomas, highlighting the gastrointestinal stromal tumours as a model for developing effective biomarkers, and notes that ongoing trials are exploring new treatments for patients with disease progression on imatinib. Prof. Jones emphasizes the challenges of developing a single biomarker for complex and heterogeneous sarcomas, such as angiosarcoma, osteosarcoma, and leiomyosarcoma, and suggests that a combination of functional imaging markers and tumor tissue markers is needed. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.